Preserved Autonomic Cardiovascular Regulation With Cardiac Pacemaker Inhibition: A Crossover Trial Using High-Fidelity Cardiovascular Phenotyping
Karsten Heusser, Jens Tank, Julia Brinkmann, Christoph Schroeder, Marcus May, Anika Großhennig, Daniela Wenzel, André Diedrich, Fred C G J Sweep, Heidrun Mehling, Friedrich C Luft, Jens Jordan, Karsten Heusser, Jens Tank, Julia Brinkmann, Christoph Schroeder, Marcus May, Anika Großhennig, Daniela Wenzel, André Diedrich, Fred C G J Sweep, Heidrun Mehling, Friedrich C Luft, Jens Jordan
Abstract
Background: Sympathetic and parasympathetic influences on heart rate (HR), which are governed by baroreflex mechanisms, are integrated at the cardiac sinus node through hyperpolarization-activated cyclic nucleotide-gated channels (HCN4). We hypothesized that HCN4 blockade with ivabradine selectively attenuates HR and baroreflex HR regulation, leaving baroreflex control of muscle sympathetic nerve activity intact.
Methods and results: We treated 21 healthy men with 2×7.5 mg ivabradine or placebo in a randomized crossover fashion. We recorded electrocardiogram, blood pressure, and muscle sympathetic nerve activity at rest and during pharmacological baroreflex testing. Ivabradine reduced normalized HR from 65.9±8.1 to 58.4±6.2 beats per minute (P<0.001) with unaffected blood pressure and muscle sympathetic nerve activity. On ivabradine, cardiac and sympathetic baroreflex gains and blood pressure responses to vasoactive drugs were unchanged. Ivabradine aggravated bradycardia during baroreflex loading.
Conclusions: HCN4 blockade with ivabradine reduced HR, leaving physiological regulation of HR and muscle sympathetic nerve activity as well as baroreflex blood pressure buffering intact. Ivabradine could aggravate bradycardia during parasympathetic activation.
Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00865917.
Keywords: autonomic nervous system; baroreflex control; funny channel; heart rate; hemodynamics; inhibitor; microneurography; pharmacology; physiology; sinoatrial node.
© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
Figures
References
- Brown HF, DiFrancesco D, Noble SJ. How does adrenaline accelerate the heart? Nature. 1979;280:235–236.
- DiFrancesco D, Tromba C. Muscarinic control of the hyperpolarization‐activated current (If) in rabbit sino‐atrial node myocytes. J Physiol. 1988;405:493–510.
- Schulze‐Bahr E, Neu A, Friederich P, Kaupp UB, Breithardt G, Pongs O, Isbrandt D. Pacemaker channel dysfunction in a patient with sinus node disease. J Clin Invest. 2003;111:1537–1545.
- Harzheim D, Pfeiffer KH, Fabritz L, Kremmer E, Buch T, Waisman A, Kirchhof P, Kaupp UB, Seifert R. Cardiac pacemaker function of HCN4 channels in mice is confined to embryonic development and requires cyclic AMP. EMBO J. 2008;27:692–703.
- Doan TN, Stephans K, Ramirez AN, Glazebrook PA, Andresen MC, Kunze DL. Differential distribution and function of hyperpolarization‐activated channels in sensory neurons and mechanosensitive fibers. J Neurosci. 2004;24:3335–3343.
- Li YL, Tran TP, Muelleman R, Schultz HD. Blunted excitability of aortic baroreceptor neurons in diabetic rats: involvement of hyperpolarization‐activated channel. Cardiovasc Res. 2008;79:715–721.
- DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64:1757–1765.
- Bucchi A, Baruscotti M, Nardini M, Barbuti A, Micheloni S, Bolognesi M, DiFrancesco D. Identification of the molecular site of ivabradine binding to HCN4 channels. PLoS One. 2013;8:e53132.
- Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost‐Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo‐controlled study. Lancet. 2010;376:875–885.
- Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double‐blind, multicentered, placebo‐controlled trial. Circulation. 2003;107:817–823.
- Schroeder C, Heusser K, Zoerner AA, Grosshennig A, Wenzel D, May M, Sweep FC, Mehling H, Luft FC, Tank J, Jordan J. Pacemaker current inhibition in experimental human cardiac sympathetic activation: a double‐blind, randomized, crossover study. Clin Pharmacol Ther. 2014;95:601–607.
- Bucchi A, Baruscotti M, DiFrancesco D. Current‐dependent block of rabbit sino‐atrial node I(f) channels by ivabradine. J Gen Physiol. 2002;120:1–13.
- Courtney KR. Mechanism of frequency‐dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol Exp Ther. 1975;195:225–236.
- DiFrancesco D. Cardiac pacemaker I(f) current and its inhibition by heart rate‐reducing agents. Curr Med Res Opin. 2005;21:1115–1122.
- Willemsen JJ, Sweep CG, Lenders JW, Ross HA. Stability of plasma free metanephrines during collection and storage as assessed by an optimized HPLC method with electrochemical detection. Clin Chem. 2003;49:1951–1953.
- Tank J, Heusser K, Malehsa D, Hegemann K, Haufe S, Brinkmann J, Tegtbur U, Diedrich A, Bara C, Jordan J, Struber M. Patients with continuous‐flow left ventricular assist devices provide insight in human baroreflex physiology. Hypertension. 2012;60:849–855.
- Dupont WD, Plummer WD Jr. PS: Power and sample size calculation. 2009. Available at: . Accessed January 05, 2016.
- Hills M, Armitage P. The two‐period cross‐over clinical trial. Br J Clin Pharmacol. 1979;8:7–20.
- Jordan J, Tank J, Shannon JR, Diedrich A, Lipp A, Schroder C, Arnold G, Sharma AM, Biaggioni I, Robertson D, Luft FC. Baroreflex buffering and susceptibility to vasoactive drugs. Circulation. 2002;105:1459–1464.
- Nof E, Luria D, Brass D, Marek D, Lahat H, Reznik‐Wolf H, Pras E, Dascal N, Eldar M, Glikson M. Point mutation in the HCN4 cardiac ion channel pore affecting synthesis, trafficking, and functional expression is associated with familial asymptomatic sinus bradycardia. Circulation. 2007;116:463–470.
- Duhme N, Schweizer PA, Thomas D, Becker R, Schroter J, Barends TR, Schlichting I, Draguhn A, Bruehl C, Katus HA, Koenen M. Altered HCN4 channel C‐linker interaction is associated with familial tachycardia‐bradycardia syndrome and atrial fibrillation. Eur Heart J. 2013;34:2768–2775.
- Ueda K, Nakamura K, Hayashi T, Inagaki N, Takahashi M, Arimura T, Morita H, Higashiuesato Y, Hirano Y, Yasunami M, Takishita S, Yamashina A, Ohe T, Sunamori M, Hiraoka M, Kimura A. Functional characterization of a trafficking‐defective HCN4 mutation, D553N, associated with cardiac arrhythmia. J Biol Chem. 2004;279:27194–27198.
- Milanesi R, Baruscotti M, Gnecchi‐Ruscone T, DiFrancesco D. Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel. N Engl J Med. 2006;354:151–157.
- Herrmann S, Stieber J, Stockl G, Hofmann F, Ludwig A. HCN4 provides a “depolarization reserve” and is not required for heart rate acceleration in mice. EMBO J. 2007;26:4423–4432.
- Li P, Lines GT, Maleckar MM, Tveito A. Mathematical models of cardiac pacemaking function. Front Phys. 2013;1:1–13.
- Yaniv Y, Maltsev VA. Numerical modeling calcium and CaMKII effects in the SA node. Front Pharmacol. 2014;5:58.
- Kurata Y, Matsuda H, Hisatome I, Shibamoto T. Roles of hyperpolarization‐activated current If in sinoatrial node pacemaking: insights from bifurcation analysis of mathematical models. Am J Physiol Heart Circ Physiol. 2010;298:H1748–H1760.
- Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091–1099.
- Tank J, Heusser K, Diedrich A, Luft FC, Jordan J. A novel pharmacological approach to determining parasympathetic heart rate reserve in human subjects. Clin Pharmacol Ther. 2010;88:630–633.
- Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck‐Brentano C, Jaillon P. Pharmacokinetic‐pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther. 1998;64:192–203.
- Seifert R, Scholten A, Gauss R, Mincheva A, Lichter P, Kaupp UB. Molecular characterization of a slowly gating human hyperpolarization‐activated channel predominantly expressed in thalamus, heart, and testis. Proc Natl Acad Sci USA. 1999;96:9391–9396.
- Hughes DI, Boyle KA, Kinnon CM, Bilsland C, Quayle JA, Callister RJ, Graham BA. HCN4 subunit expression in fast‐spiking interneurons of the rat spinal cord and hippocampus. Neuroscience. 2013;237:7–18.
- Tank J, Diedrich A, Szczech E, Luft FC, Jordan J. Alpha‐2 adrenergic transmission and human baroreflex regulation. Hypertension. 2004;43:1035–1041.
- Tank J, Schroeder C, Diedrich A, Szczech E, Haertter S, Sharma AM, Luft FC , Jordan J. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation. 2003;107:2949–2954.
- Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N, Strauss A, Stoffels G, Luft FC, Jordan J. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther. 2006;79:500–508.
- Jiang J, Tian L, Huang Y, Li Y, Xu L. Pharmacokinetic and safety profile of ivabradine in healthy Chinese men: a phase I, randomized, open‐label, increasing single‐ and multiple‐dose study. Clin Ther. 2013;35:1933–1945.
- Komlev AD, Kuziaev AI, Laskin GM, Kuzenkova VE, Kolosova MV. Effect of the I(f) channel blocker ivabradine on the parameters of external respiration function in patients with chronic obstructive pulmonary disease in its stable course period. Ter Arkh. 2010;82:23–25.
- Jacob G, Costa F, Shannon JR, Robertson RM, Wathen M, Stein CM, Biaggioni I, Ertl A, Black B, Robertson D. The neuropathic postural tachycardia syndrome. N Engl J Med. 2000;343:1008–1014.
- Furlan R, Jacob G, Snell M, Robertson D, Porta A, Harris P, Mosqueda‐Garcia R. Chronic orthostatic intolerance: a disorder with discordant cardiac and vascular sympathetic control. Circulation. 1998;98:2154–2159.
- McDonald C, Frith J, Newton JL. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace. 2011;13:427–430.
- Stillitano F, Lonardo G, Giunti G, Del LM, Coppini R, Spinelli V, Sartiani L, Poggesi C, Mugelli A, Cerbai E. Chronic atrial fibrillation alters the functional properties of If in the human atrium. J Cardiovasc Electrophysiol. 2013;24:1391–1400.
- Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257–1263.
- McCance AJ, Thompson PA, Forfar JC. Increased cardiac sympathetic nervous activity in patients with unstable coronary heart disease. Eur Heart J. 1993;14:751–757.
Source: PubMed